MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1093/rheumatology/kead068

Медицинская библиотека · Rheumatology (Oxford, England) · 2023

A novel TNFRSF1A mutation associated with TNF-receptor-associated periodic syndrome and its metabolic signature.

Steiner Joachim D, Annibal Andrea, Laboy Raymond, Braumann Marie, Göbel Heike, Laasch Valentin, Müller Roman-Ulrich, Späth Martin R, Antebi Adam, Kubacki Torsten

СтатьяПоддержка исследования: вне правительства СШАПеревод пока не подготовлен

Аннотация

OBJECTIVE

We describe a family with a novel mutation in the TNF Receptor Superfamily Member 1A (TNFRSF1A) gene causing TNF receptor-associated periodic syndrome (TRAPS) with renal AA amyloidosis.

METHODS

Case series of affected family members. We further investigated the plasma metabolome of these patients in comparison with healthy controls using mass spectrometry.

RESULTS

In all symptomatic family members, we detected the previously undescribed variant c.332A>G (p.Q111R) in the TNFRSF1A gene. Canakinumab proved an effective treatment option leading to remission in all treated patients. One patient with suspected renal amyloidosis showed near normalization of proteinuria under treatment. Analysis of the metabolome revealed 31 metabolic compounds to be upregulated and 35 compounds to be downregulated compared with healthy controls. The most dysregulated metabolites belonged to pathways identified as arginine biosynthesis, phenylalanine, tyrosine and tryptophan biosynthesis, and cysteine and methionine metabolism. Interestingly, the metabolic changes observed in all three TRAPS patients seemed independent of treatment with canakinumab and subsequent remission.

CONCLUSION

We present a novel mutation in the TNFRSF1A gene associated with amyloidosis. Canakinumab is an effective treatment for individuals with this new likely pathogenic variant. Alterations in the metabolome were most prominent in the pathways related to arginine biosynthesis, tryptophan metabolism, and metabolism of cysteine and methionine, and seemed to be unaffected by treatment with canakinumab. Further investigation is needed to determine the role of these metabolomic changes in the pathophysiology of TRAPS.

Для цитирования: Steiner Joachim D, Annibal Andrea, Laboy Raymond, Braumann Marie, Göbel Heike, Laasch Valentin, Müller Roman-Ulrich, Späth Martin R, Antebi Adam, Kubacki Torsten. A novel TNFRSF1A mutation associated with TNF-receptor-associated periodic syndrome and its metabolic signature.. Rheumatology (Oxford, England). 2023. DOI: 10.1093/rheumatology/kead068.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.